VG Health

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ENTA

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Enanta Pharma's RSV Bet And Immunology Ambitions

BCRX

QNRX

The Netherton syndrome market is projected to grow from 2026 to 2036, driven by new therapies like QRX003, BCX17725, and ATR-12. The U.S. is expected to lead in market size, with an increase in diagnosed cases due to better diagnostics. Current treatments are mainly symptomatic, highlighting the need for effective, targeted therapies. The development of these new drugs presents significant opportunities in addressing the unmet medical needs of Netherton syndrome patients.

prnewswire

BioCryst Pharma

Quoin Pharmaceuticals

Azitra

QUOIN PHARMACEUTICALS LTD SPON ADS EACH REP 1 ORD SHS

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

IMUX

BIIB

Immunic has appointed Michael W. Bonney as chair of the board, effective May 16, 2026, replacing interim chair Simona Skerjanec, who will remain a board member. Bonney has a strong background in the pharmaceutical industry, having previously held senior roles at Biogen and served as CEO of Cubist Pharmaceuticals, leading its sale to Merck for approximately USD 9.5 billion.

PUBT

Immunic

Merck

Biogen

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

BMRN

BioMarin Pharmaceutical (BMRN) has seen a decline in its stock price, down 4% in a day and 17% over three months, raising concerns about its valuation. Currently priced at $49.67, analysts estimate a fair value of $89.96, indicating potential undervaluation. However, there is significant disagreement among analysts regarding future earnings projections. The company's high P/E ratio of 35.7x compared to industry averages suggests valuation risks. Investors are advised to consider both opportunities and risks before making decisions.

Simplywall

BioMarin Pharma

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

NAII

Natural Alternatives International reported a Q3 FY26 net loss of $4.31 million, a 97% increase from $2.19 million a year prior. Net sales rose 23% to $35.48 million, but gross profit fell to $383,000, reducing gross margin to 1.1%. The operating loss widened to $4.01 million. For the nine months, net sales increased 13% to $108.01 million, with a narrowed operating loss of $5.58 million. Management anticipates higher fourth-quarter sales but expects continued net losses and plans to sell its headquarters to improve liquidity.

Natural Alternatives

Natural Alternatives’ Q3 FY26 net loss widens 97% to $4.31 million

RLAY

Relay Therapeutics reported a 60% response rate in its Phase 2 trial of zovegalisib for PIK3CA-driven vascular anomalies, with significant lesion shrinkage and symptom improvement in evaluable patients. The interim safety profile supports chronic dosing, and expansion cohorts are now using lower-dose regimens for adults and adolescents, while pediatric dose-finding continues.

Relay Therapeutics

Relay Therapeutics reports 60% response rate in Phase 2 zovegalisib vascular anomalies trial

WHO REPRESENTATIVE IN CONGO: MERCK & CO’S >< ERVEBO IS ONE OF THE POTENTIAL VACCINES THAT COULD PROVIDE PREVENTION AND PROTECTION AGAINST EBOLA

Unusual Whales

WHO REPRESENTATIVE IN CONGO: MERCK & CO’S >< ERVEBO IS ONE OF THE POTENTIAL VACCINES THAT COULD PROVIDE PREVENTION AND PROTECTION AGAINST EBOLA

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

UNHG

GSA Capital Partners LLP increased its stake in UnitedHealth Group (NYSE:UNH) by 203.2% in Q4, owning 6,673 shares valued at $2.2 million. Other institutional investors also raised their holdings. Analysts have upgraded their ratings, with Barclays setting a price target of $373.00. Despite Berkshire Hathaway's exit affecting sentiment, UnitedHealth's recent earnings showed positive results, maintaining a market cap of $354.57 billion.

Unitedhealth

iShares US Healthcare Providers

SPDR S&P Health

Leverage Shares 2X Long UNH Daily ETF

Barclays

Jefferies Financial

KeyCorp

Berkshire Hathaway

Berkshire Hathaway B

Thomson Reuters

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB increased its stake in HCA Healthcare, Inc. by 7.9% in Q4, owning 213,272 shares valued at approximately $99.57 million. Other hedge funds also adjusted their positions. HCA's stock opened at $422.60, with a market cap of $93.75 billion. The company reported Q1 earnings of $7.15 per share, slightly below estimates, and announced a quarterly dividend of $0.78. Analysts have varied price targets, with UBS raising theirs to $635.00.

HCA Healthcare

UBS Group AG

Goldman Sachs

Toronto Dominion Bank

ROYAL BANK OF CANADA

GS Hldg R

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA

VG Health(VHT.US)

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Enanta Pharma's RSV Bet And Immunology Ambitions

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

Natural Alternatives’ Q3 FY26 net loss widens 97% to $4.31 million

Relay Therapeutics reports 60% response rate in Phase 2 zovegalisib vascular anomalies trial

WHO REPRESENTATIVE IN CONGO: MERCK & CO’S >< ERVEBO IS ONE OF THE POTENTIAL VACCINES THAT COULD PROVIDE PREVENTION AND PROTECTION AGAINST EBOLA

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA